Palisade Asset Management’s Biogen BIIB Stock Holding History

Palisade Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$141	–	244
2025 Q3	$141	Buy	+1	New	+$135	﹤0.01%	671

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Palisade Asset Management's BIIB Position: Q4 2025 in Review

Palisade Asset Management sold out of Biogen (BIIB) in Q4 2025, closing a stake of 1 share — an estimated $141 sold.

Palisade Asset Management first reported a position in BIIB in Q3 2025 and held it in 1 quarter. The position peaked at $141 in Q3 2025. 1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Palisade Asset Management reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Palisade Asset Management sold 1 Biogen share in Q4 2025, an estimated $141.
Palisade Asset Management first reported a position in Biogen in Q3 2025 and held it in 1 quarter.
Palisade Asset Management's Biogen position peaked at $141 in Q3 2025.
1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Palisade Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.